The Ministry of Education Key Laboratory for Standardization of Chinese Medicines and the State Administration of Traditional Chinese Medicine Key Laboratory for New Resources and Quality Evaluation of Chinese Medicines, Institute of Chinese Materia Medica, Shanghai University of Traditional Chinese Medicine, 1200 Cailun Road, Shanghai, 201203, China.
The Ministry of Education Key Laboratory for Standardization of Chinese Medicines and the State Administration of Traditional Chinese Medicine Key Laboratory for New Resources and Quality Evaluation of Chinese Medicines, Institute of Chinese Materia Medica, Shanghai University of Traditional Chinese Medicine, 1200 Cailun Road, Shanghai, 201203, China; Shanghai R & D Center for Standardization of Traditional Chinese Medicines, Shanghai, 201203, China.
Toxicol Lett. 2020 May 1;323:41-47. doi: 10.1016/j.toxlet.2020.01.021. Epub 2020 Jan 23.
Gynura japonica (also named Tusanqi in Chinese) is used as a folk herbal medicine for treating blood stasis or traumatic injury. However, hundreds of hepatic sinusoidal obstruction syndrome (HSOS) cases have been reported after consumption of preparations made from G. japonica because it contains large amounts of hepatotoxic pyrrolizidine alkaloids (PAs). To date, blood pyrrole-protein adducts (PPAs) are suggested as biomarkers for the diagnosis of PA-induced HSOS in clinics. However, the concentration of PPAs in the blood is greatly affected by several factors including the amount of PA exposure, herb intake period, and blood sampling time after the last exposure. In present study, the kinetic characters of PPAs in serum and liver as well as other potential target organs were studied systematically and comprehensively following multiple exposures of PAs in G. japonica extract (GJE). As results, PPAs content reached to a plateau both in serum and liver after the mice were treated with GJE for 2 weeks on daily basis. PPAs cleared significantly slower in liver (T184.6 h, ∼7.7 days) than in serum (T∼95.8 h, ∼4.0 days). Although more than 90 % PPAs were removed 2 weeks after the last dosing, PPAs still persisted in the liver until the end of the experiment, i.e. 8 weeks after the last dosing. The results would be of great help for understanding the importance of PPAs for PA-induced toxicity and its detoxification.
三叶鬼针草(在中国也被称为“鬼针草”)被用作民间草药,用于治疗血瘀或创伤损伤。然而,由于其含有大量肝毒性吡咯里西啶生物碱(PAs),大量因食用由三叶鬼针草制成的制剂而导致肝窦阻塞综合征(HSOS)的病例报告。迄今为止,血液吡咯蛋白加合物(PPAs)被认为是临床诊断 PA 诱导的 HSOS 的生物标志物。然而,PPAs 在血液中的浓度受到多种因素的极大影响,包括 PA 暴露量、草药摄入期以及最后一次暴露后采血时间。在本研究中,系统而全面地研究了多次暴露于三叶鬼针草提取物(GJE)中的 PA 后,血清和肝脏以及其他潜在靶器官中 PPAs 的动力学特征。结果表明,每天用 GJE 处理小鼠 2 周后,PPAs 在血清和肝脏中的含量均达到平台期。PPAs 在肝脏中的清除速度明显慢于血清(T184.6 h,∼7.7 天)。尽管在最后一次给药后 2 周内清除了超过 90%的 PPAs,但直到实验结束,即最后一次给药后 8 周,PPAs 仍在肝脏中持续存在。这些结果将有助于了解 PPAs 在 PA 诱导的毒性及其解毒中的重要性。